-+ 0.00%
-+ 0.00%
-+ 0.00%

Argenx Unit Kicks Off Tender Offer to Buy Forte Biosciences

MT Newswires·08/06/2026 08:48:17
Listen to the news
08:48 AM EDT, 08/06/2026 (MT Newswires) -- Argenx's (ARGX.BR) subsidiary Avena Merger Sub launched a tender offer to acquire all issued and outstanding shares of US clinical-stage biopharmaceutical company Forte Biosciences for $77 per share in cash. Under the terms of a previously agreed merger plan, the immunology company's unit will merge with and into Forte, making the latter a wholly owned subsidiary of argenx, according to a Thursday release. The tender offer will expire on Aug. 26, unless extended or terminated early.